Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 50Letrozole 44Fulvestrant 44Paclitaxel 39pembrolizumab 34Magnetic Resonance Spectroscopy 32Carboplatin 31Trastuzumab 27Biopsy 27ribociclib 26Capecitabine 24Anastrozole 24palbociclib 23exemestane 23trastuzumab deruxtecan 20pertuzumab 20Tamoxifen 20abemaciclib 19Cyclophosphamide 17Taxes 15Radiotherapy 15130-nm albumin-bound paclitaxel 12elacestrant 11Docetaxel 11Standard of Care 10Gemcitabine 10sacituzumab govitecan 9olaparib 9eribulin 9Radiation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ivermectin × Breast × 30 days × Clear all
NCT05318469 2026-05-06

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 1/2 Recruiting
34 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡